T-cell-targeted immunotherapy in neurofibromatosis type 2-related vestibular schwannoma: current evidence and future direction

Neurofibromatosis type 2-related schwannomatosis is a rare tumour predisposition syndrome caused by loss-of-function pathogenic variants within the NF2 gene, which encodes the tumour suppressor protein merlin. This leads to development of benign tumours within the nervous system, most notably vestibular schwannomas that form on the vestibulocochlear (eighth cranial) nerve....

No actionable change for current audiology or neurotology practice; T-cell immunotherapy for NF2-related schwannomas remains investigational with no approved clinical protocol.

NF2-related vestibular schwannomas are notoriously difficult to manage and often lead to profound hearing loss; emerging immunotherapy options could eventually change the treatment landscape for this population.

1. 01Neurofibromatosis type 2 (NF2) is a rare inherited condition caused by loss-of-function variants in the NF2 gene, causing bilateral vestibular schwannomas.
2. 02T-cell-targeted immunotherapies (immune cell treatments) are being explored as alternatives to surgery and radiation.
3. 03Current evidence for immunotherapy in NF2-related schwannoma is limited and still largely preclinical or early-phase.
4. 04The review outlines future research directions including novel T-cell strategies.
5. 05Hearing preservation is a key clinical concern driving interest in non-surgical therapies.

PMID

42272870

DOI

10.1093/braincomms/fcag192.

Journal

Brain Communications

Publication type

review

Evidence level

5

Population

Patients with neurofibromatosis type 2 (NF2)-related vestibular schwannoma

Intervention

T-cell-targeted immunotherapy